Chronic Clinical Trials in Boston, Massachusetts
134 recruitingBoston, Massachusetts
Showing 1–20 of 134 trials
Recruiting
Phase 2
Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia
Recurrent Chronic Lymphocytic LeukemiaRecurrent Small Lymphocytic LymphomaRefractory Chronic Lymphocytic Leukemia+1 more
National Cancer Institute (NCI)20 enrolled6 locationsNCT07061951
Recruiting
A Registry for People With T-cell Lymphoma
T-cell LymphomaNK-Cell LymphomaT-cell Prolymphocytic Leukemia+27 more
Memorial Sloan Kettering Cancer Center1,000 enrolled26 locationsNCT05978141
Recruiting
Phase 2
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
Loxo Oncology, Inc.249 enrolled131 locationsNCT06588478
Recruiting
Phase 3
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
National Cancer Institute (NCI)247 enrolled629 locationsNCT04269902
Recruiting
Phase 3
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
BeOne Medicines630 enrolled170 locationsNCT06943872
Recruiting
Phase 3
A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
BeOne Medicines500 enrolled149 locationsNCT06973187
Recruiting
Phase 3
A Long-term Extension Study of PCI-32765 (Ibrutinib)
Diffuse Large B Cell LymphomaChronic Lymphocytic LeukemiaMantle Cell Lymphoma+4 more
Janssen Research & Development, LLC700 enrolled175 locationsNCT01804686
Recruiting
Phase 2
Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)
Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Leukemia (SLL)
Memorial Sloan Kettering Cancer Center230 enrolled8 locationsNCT03824483
Recruiting
Understanding Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
Dana-Farber Cancer Institute2,750 enrolled1 locationNCT04028531
Recruiting
Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies
Lymphoproliferative DisordersNon-Hodgkin's LymphomaHodgkin's Disease+1 more
Dana-Farber Cancer Institute1,500 enrolled1 locationNCT00131014
Recruiting
Phase 2
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaChronic Lymphocytic Leukemia+7 more
City of Hope Medical Center216 enrolled3 locationsNCT06059391
Recruiting
Phase 1Phase 2
Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
Leukemia, Lymphocytic, Chronic, B-CellLymphoma, Small Lymphocytic
Juno Therapeutics, a Subsidiary of Celgene320 enrolled86 locationsNCT03331198
Recruiting
Phase 1Phase 2
Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)
Chronic Lymphocytic LeukemiaLeukemiaRelapsed Leukemia+2 more
Jennifer R. Brown, MD, PhD64 enrolled1 locationNCT06644183
Recruiting
Phase 1Phase 2
Mosunetuzumab for CLL MRD Clearance
Chronic Lymphocytic LeukemiaLymphomaLeukemia+1 more
Inhye Ahn40 enrolled2 locationsNCT07052695
Recruiting
Phase 2
Zanubrutinib and Venetoclax in CLL (ZANU-VEN)
Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)
Dana-Farber Cancer Institute45 enrolled4 locationsNCT05168930
Recruiting
Phase 1
ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML
B-cell Acute Lymphoblastic LeukemiaChronic Myeloid Leukemia (CML) in Lymphoid Blast CrisisPhiladelphia Chromosome Positive Acute Lymphoblastic Leukemia Ph+ ALL
Marlise Luskin, MD40 enrolled4 locationsNCT03595917
Recruiting
The Impact of Renal Transplant on Coronary Microvascular Function Among Patients With Advanced Chronic Kidney Disease
Kidney TransplantChronic Kidney DiseaseInflammation+1 more
Brigham and Women's Hospital80 enrolled1 locationNCT07222683
Recruiting
Prospective Study of Sensation and Satisfaction in Cancer and Transgender Mastectomy Patients
Pain, ChronicPain, PostoperativeSensation Disorders+6 more
Weill Medical College of Cornell University400 enrolled2 locationsNCT06094257
Recruiting
Phase 1
Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
Hematologic MalignancyGvHDGVHD,Acute+8 more
Tr1X, Inc.36 enrolled5 locationsNCT06462365
Recruiting
Phase 1
Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies
Castrate Resistant Prostate CancerNUT CarcinomaChronic Myelomonocytic Leukemia+1 more
Epigenetix, Inc.75 enrolled6 locationsNCT05488548